Multiscale mapping of transcriptomic signatures for cardiotoxic drugs-Reference-Cited by-同舟云学术

Multiscale mapping of transcriptomic signatures for cardiotoxic drugs

Published:2024-09-11 Issue:1 Volume:15 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Hansen Jens^ORCID,Xiong Yuguang^ORCID,Siddiq Mustafa M.,Dhanan Priyanka,Hu Bin,Shewale Bhavana,Yadaw Arjun S.,Jayaraman Gomathi,Tolentino Rosa E.,Chen Yibang,Martinez Pedro,Beaumont Kristin G.^ORCID,Sebra Robert^ORCID,Vidovic Dusica,Schürer Stephan C.,Goldfarb Joseph,Gallo James M.^ORCID,Birtwistle Marc R.^ORCID,Sobie Eric A.,Azeloglu Evren U.^ORCID,Berger Seth I.^ORCID,Chan Angel^ORCID,Schaniel Christoph^ORCID,Dubois Nicole C.^ORCID,Iyengar Ravi^ORCID

Funder

U.S. Department of Health & Human Services | National Institutes of Health

U.S. Department of Health & Human Services | U.S. Food and Drug Administration

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41467-024-52145-4.pdf

Reference99 articles.

1. de Vries, E. N., Ramrattan, M. A., Smorenburg, S. M., Gouma, D. J. & Boermeester, M. A. The incidence and nature of in-hospital adverse events: a systematic review. Qual. Saf. Health Care 17, 216–223 (2008).

2. Drozda, K., Pacanowski, M. A., Grimstein, C. & Zineh, I. Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective. JACC Basic Transl. Sci. 3, 545–549 (2018).

3. Smith, A. F., Klotz, A. & Wormstone, I. M. Improving the drug development process by reducing the impact of adverse events: the case of cataracts considered. Drug Discov. Today 21, 510–516 (2016).

4. Dorato, M. A. & Buckley, L. A. Toxicology in the drug discovery and development process. Curr. Protoc. Pharmacol. Chapter 10, Unit10 13 https://doi.org/10.1002/0471141755.ph1003s32 (2006).

5. Ma’ayan, A., Jenkins, S. L., Goldfarb, J. & Iyengar, R. Network analysis of FDA approved drugs and their targets. Mt Sinai J. Med. 74, 27–32 (2007).